Premium
The intracerebral application of the PPARγ‐ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain
Author(s) -
Zhao Yi,
Patzer Andreas,
Gohlke Peter,
Herdegen Thomas,
Culman Juraj
Publication year - 2005
Publication title -
european journal of neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.346
H-Index - 206
eISSN - 1460-9568
pISSN - 0953-816X
DOI - 10.1111/j.1460-9568.2005.04200.x
Subject(s) - pioglitazone , neuroprotection , microglia , medicine , pharmacology , peroxisome proliferator activated receptor , ischemia , anesthesia , receptor , inflammation , endocrinology , type 2 diabetes , diabetes mellitus
The present study addresses the neuroprotective function of intracerebroventricular (i.c.v.) application of pioglitazone, a selective ligand of the peroxisome proliferator‐activated receptor gamma (PPARγ) in the rat brain after ischaemia. Pioglitazone or vehicle were i.c.v. infused via osmotic minipumps over a 5‐day period before, and 2 days after transient middle cerebral artery occlusion (MCAO) for 90 min. This i.c.v. application of pioglitazone in the brain significantly reduced the infarct size and brain oedema, and attenuated in the peri‐infarct cortical regions the invasion of activated microglia and macrophages. Moreover, pioglitazone improved the recovery of sensory deficits 48 h after MCAO. Our data demonstrate for the first time that it is the activation of intracerebral PPARγ that can confer neuroprotection, anti‐inflammatory and neurological improvement following ischaemic injury.